Researchers are engineering peptides that hold up in the gut and aim at specific cells, which could let precision medicines be taken by mouth instead of injected.
Recap by typeshit. Full story at The Kansas City Star on MSN.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
The CHMP recommended approval of orforglipron, a once-daily GLP-1 pill with no food or water rules. The European Commission usually decides within weeks.
CME India covers an October 14 study reporting retatrutide side effects outside the gut, including a signal that the drug may paradoxically raise appetite.
Loading…